Literature DB >> 15168907

Characterization of nicotinic receptors inducing noradrenaline release and absence of nicotinic autoreceptors in human neocortex.

Florian Amtage1, Bogdan Neughebauer, J Michael McIntosh, Thomas Freiman, Josef Zentner, Thomas J Feuerstein, Rolf Jackisch.   

Abstract

UNLABELLED: Presynaptic facilitatory nicotinic receptors (nAChRs) on noradrenergic axon terminals were studied in slices of human or rat neocortex and of rat hippocampus preincubated with [3H]noradrenaline ([3H]NA). During superfusion of the slices, stimulation by nicotinic agonists for 2 min only slightly increased [3H]NA outflow in the rat neocortex, but caused a tetrodotoxin-sensitive. Ca(2+)-dependent release of [3H]NA in rat hippocampus and human neocortex. In both tissues a similar rank order of potency of nicotinic agonists was found: epibatidine >> DMPP > nicotine approximately cytisine > or = acetylcholine; choline was ineffective. In human neocortex, the effects of nicotine (100 microM) were reduced by mecamylamine, methyllycaconitine, di-hydro-beta-erythroidine (10 microM, each) and the alpha3beta2/alpha6betax-selective alpha-conotoxin MII (100/200 nM). The alpha3beta4 selective alpha-conotoxin AuIB (1 microM), and the alpha7 selective alpha-conotoxin ImI (200 nM) as well as alpha-bungarotoxin (125 nM) were ineffective. Glutamate receptor antagonists (300 microM AP-5, 100 microM DNQX) acted inhibitory, suggesting the participation of nAChRs on glutamatergic neurons. On the other hand, nAChR agonists were unable to evoke exocytotic release of [3H]acetylcholine from human and rat neocortical slices preincubated with [3H]choline. IN
CONCLUSION: (1) alpha3beta2 and/or alpha6 containing nAChRs are at least partially responsible for presynaptic cholinergic facilitation of noradrenergic transmission in human neocortex; (2) nicotinic autoreceptors were not detectable in rat and human neocortex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168907     DOI: 10.1016/j.brainresbull.2003.11.002

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

1.  The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.

Authors:  Andrew M Smith; Gurpreet K Dhawan; Zhenfa Zhang; Kiran B Siripurapu; Peter A Crooks; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2009-07-23       Impact factor: 5.858

2.  Regulation of the common carotid arterial blood flow by nicotinic receptors in the medulla of cats.

Authors:  C-L Gong; Y-T Chiu; N-N Lin; C-C Cheng; S-Z Lin; T J-F Lee; J-S Kuo
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

3.  Catecholamine outflow from mouse and rat brain slice preparations evoked by nicotinic acetylcholine receptor activation and electrical field stimulation.

Authors:  P Scholze; A Orr-Urtreger; J-P Changeux; J M McIntosh; S Huck
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 4.  Mechanistic insights into nicotine withdrawal.

Authors:  Michael Paolini; Mariella De Biasi
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

5.  The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

6.  Nicotinic receptor-evoked hippocampal norepinephrine release is highly sensitive to inhibition by isoflurane.

Authors:  R I Westphalen; R S Gomez; H C Hemmings
Journal:  Br J Anaesth       Date:  2009-02-02       Impact factor: 9.166

7.  Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors.

Authors:  K Iwamoto; D Mata; D M Linn; C L Linn
Journal:  Neuroscience       Date:  2013-02-10       Impact factor: 3.590

Review 8.  Nicotinic receptor-based therapeutics and candidates for smoking cessation.

Authors:  Linda P Dwoskin; Andrew M Smith; Thomas E Wooters; Zhenfa Zhang; Peter A Crooks; Michael T Bardo
Journal:  Biochem Pharmacol       Date:  2009-06-10       Impact factor: 5.858

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.